Skip to main content
Top
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Hepatocellular Carcinoma | Primary research

Leucine-rich repeat and sterile alpha motif containing 1 promotes the oncogenic growth of human hepatocellular carcinoma cells

Authors: Lili Pian, Xiaofeng Huang, Min Zhao, Yaolin Zhang, Cheng Qin, Jiyan Zhang, Jun Zhang, Qingyang Wang

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC), the most common primary cancer of the liver, is one of the most common malignancies and the leading cause of cancer-related death worldwide. Leucine-rich repeat and sterile alpha motif containing 1 (LRSAM1) is an E3 ubiquitin ligase involved in diverse cellular activities, including the regulation of cargo sorting, cell adhesion and antibacterial autophagy. The role of LRSAM1 in HCC remains unknown.

Methods

In this study, we reviewed the TCGA database and then performed gain-of-function and loss-of-function analyses of LRSAM1 in HCC cell lines.

Results

We found that the mRNA expression level of LRSAM1 was significantly increased in clinical HCC tissues in the TCGA database. Transient LRSAM1 knockdown in several human HCC cell lines led to reduced growth in conventional culture conditions. Stable LRSAM1 knockdown in HepG2 cells led to impaired anchorage-independent growth whereas its stable ectopic overexpression yielded the opposite effects. LRSAM1 overexpression in HepG2 cells enhanced in vivo tumorigenicity, whereas LRSAM1 knockdown in this cell line significantly impaired tumor growth.

Conclusions

Our data suggest that LRSAM1 promotes the oncogenic growth of human HCC cells, although the underlying mechanisms remain to be explored.
Appendix
Available only for authorised users
Literature
4.
go back to reference Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2016;45:529–38.CrossRef Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2016;45:529–38.CrossRef
10.
go back to reference Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, Roubini E, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev. 2004;18:1737–52.CrossRefPubMedPubMedCentral Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, Roubini E, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev. 2004;18:1737–52.CrossRefPubMedPubMedCentral
13.
go back to reference Butt G, Yaylim I, Attar R, Aras A, Romero MA, Qureshi MZ, et al. NEDD4 family of E3 ubiquitin ligases in breast cancer: spotlight on SMURFs, WWPs and NEDD4. Adv Exp Med Biol. 2019;1152:365-75.CrossRefPubMed Butt G, Yaylim I, Attar R, Aras A, Romero MA, Qureshi MZ, et al. NEDD4 family of E3 ubiquitin ligases in breast cancer: spotlight on SMURFs, WWPs and NEDD4. Adv Exp Med Biol. 2019;1152:365-75.CrossRefPubMed
19.
Metadata
Title
Leucine-rich repeat and sterile alpha motif containing 1 promotes the oncogenic growth of human hepatocellular carcinoma cells
Authors
Lili Pian
Xiaofeng Huang
Min Zhao
Yaolin Zhang
Cheng Qin
Jiyan Zhang
Jun Zhang
Qingyang Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0976-x

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine